Arcus Biosciences, Inc. Net Income
Arcus Biosciences, Inc. (RCUS) reported Net Income of -$91.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-05
- Arcus Biosciences, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$91.00M.
- Arcus Biosciences, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$128.00M.
- Arcus Biosciences, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$106.00M.
- Arcus Biosciences, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$135.00M.
- Arcus Biosciences, Inc. net income (loss) attributable to parent for fiscal 2020 was -$123.00M.
- Arcus Biosciences, Inc. net income (loss) attributable to parent for fiscal 2019 was -$84.71M.
- Arcus Biosciences, Inc. net income (loss) attributable to parent for fiscal 2018 was -$49.59M.
- Arcus Biosciences, Inc. net income (loss) attributable to parent for fiscal 2017 was -$53.08M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$91.00M 10-Q · filed 2026-08-05 | -$219.00M 10-Q · filed 2026-08-05 | -$325.00M derived: sum of 3 quarters · filed 2026-08-05 | -$460.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$128.00M 10-Q · filed 2026-08-05 | -$234.00M derived: sum of 2 quarters · filed 2026-08-05 | -$369.00M derived: sum of 3 quarters · filed 2026-08-05 | -$369.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | -$106.00M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-21 | -$241.00M derived: sum of 2 quarters · filed 2026-04-21 | -$241.00M derived: sum of 3 quarters · filed 2026-08-05 | -$353.00M DEF 14A · filed 2026-04-21 | ||||
| 2025-09-30 | -$135.00M 10-Q · filed 2025-10-28 | -$135.00M derived: sum of 2 quarters · filed 2026-08-05 | -$247.00M 10-Q · filed 2025-10-28 | -$341.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 | -$112.00M 10-Q · filed 2026-08-05 | -$206.00M derived: sum of 3 quarters · filed 2026-08-05 | -$298.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$112.00M 10-Q · filed 2026-08-05 | -$206.00M derived: sum of 2 quarters · filed 2026-08-05 | -$298.00M derived: sum of 3 quarters · filed 2026-08-05 | -$391.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2024-12-31 | -$94.00M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-21 | -$186.00M derived: sum of 2 quarters · filed 2026-04-21 | -$279.00M derived: sum of 3 quarters · filed 2026-04-21 | -$283.00M DEF 14A · filed 2026-04-21 | ||||
| 2024-09-30 | -$92.00M 10-Q · filed 2025-10-28 | -$185.00M derived: sum of 2 quarters · filed 2025-10-28 | -$189.00M 10-Q · filed 2025-10-28 | -$270.00M derived: sum of 4 quarters · filed 2026-04-21 | ||||
| 2024-06-30 | -$93.00M 10-Q · filed 2025-10-28 | -$97.00M 10-Q · filed 2025-08-06 | -$178.00M derived: sum of 3 quarters · filed 2026-04-21 | -$249.00M derived: sum of 4 quarters · filed 2026-04-21 | ||||
| 2024-03-31 | -$4.00M 10-Q · filed 2025-10-28 | -$85.00M derived: sum of 2 quarters · filed 2026-04-21 | -$156.00M derived: sum of 3 quarters · filed 2026-04-21 | -$231.00M derived: sum of 4 quarters · filed 2026-04-21 | ||||
| 2023-12-31 | -$81.00M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-21 | -$152.00M derived: sum of 2 quarters · filed 2026-04-21 | -$227.00M derived: sum of 3 quarters · filed 2026-04-21 | -$307.00M DEF 14A · filed 2026-04-21 | ||||
| 2023-09-30 | -$71.00M 10-Q · filed 2024-11-06 | -$146.00M derived: sum of 2 quarters · filed 2024-11-06 | -$226.00M 10-Q · filed 2024-11-06 | -$293.00M derived: sum of 4 quarters · filed 2026-04-21 | ||||
| 2023-06-30 | -$75.00M 10-Q · filed 2024-11-06 | -$155.00M 10-Q · filed 2024-08-08 | -$222.00M derived: sum of 3 quarters · filed 2026-04-21 | -$287.00M derived: sum of 4 quarters · filed 2026-04-21 | ||||
| 2023-03-31 | -$80.00M 10-Q · filed 2024-11-06 | -$147.00M derived: sum of 2 quarters · filed 2026-04-21 | -$212.00M derived: sum of 3 quarters · filed 2026-04-21 | -$279.00M derived: sum of 4 quarters · filed 2026-04-21 | ||||
| 2022-12-31 | -$67.00M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-21 | -$132.00M derived: sum of 2 quarters · filed 2026-04-21 | -$199.00M derived: sum of 3 quarters · filed 2026-04-21 | -$267.00M DEF 14A · filed 2026-04-21 | ||||
| 2022-09-30 | -$65.00M 10-Q · filed 2023-11-07 | -$64.92M 10-Q · filed 2022-11-02 | -$132.00M derived: sum of 2 quarters · filed 2023-11-07 | -$200.00M 10-Q · filed 2023-11-07 | -$199.54M 10-Q · filed 2022-11-02 | $79.54M derived: sum of 4 quarters · filed 2026-04-21 | ||
| 2022-06-30 | -$67.00M 10-Q · filed 2023-11-07 | -$66.63M 10-Q · filed 2022-08-03 | -$135.00M 10-Q · filed 2023-08-07 | -$134.63M 10-Q · filed 2022-08-03 | $144.54M derived: sum of 3 quarters · filed 2026-04-21 | $66.56M derived: sum of 4 quarters · filed 2026-04-21 | ||
| 2022-03-31 | -$68.00M 10-Q · filed 2023-11-07 | -$67.99M 10-Q · filed 2022-05-09 | $211.54M derived: sum of 2 quarters · filed 2026-04-21 | $133.56M derived: sum of 3 quarters · filed 2026-04-21 | $57.59M derived: sum of 4 quarters · filed 2026-04-21 | |||
| 2021-12-31 | $279.54M derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-21 | $201.56M derived: sum of 2 quarters · filed 2026-04-21 | $125.59M derived: sum of 3 quarters · filed 2026-04-21 | $53.00M DEF 14A · filed 2026-04-21 | $52.83M 10-K · filed 2022-02-23 | |||
| 2021-09-30 | -$77.97M 10-Q · filed 2022-11-02 | -$153.94M derived: sum of 2 quarters · filed 2022-11-02 | -$226.54M 10-Q · filed 2022-11-02 | -$278.39M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | -$75.97M 10-Q · filed 2022-11-02 | -$148.56M 10-Q · filed 2022-08-03 | -$200.42M derived: sum of 3 quarters · filed 2022-11-02 | -$198.59M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-03-31 | -$72.59M 10-Q · filed 2022-11-02 | -$124.45M derived: sum of 2 quarters · filed 2022-11-02 | -$122.62M derived: sum of 3 quarters · filed 2022-11-02 | -$167.70M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2020-12-31 | -$51.85M 10-K · filed 2021-02-25 | -$50.03M derived: sum of 2 quarters · filed 2021-11-08 | -$95.11M derived: sum of 3 quarters · filed 2021-11-08 | -$123.00M 10-K · filed 2023-02-28 | -$122.86M 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $1.82M 10-Q · filed 2021-11-08 | -$43.25M derived: sum of 2 quarters · filed 2021-11-08 | -$71.00M 10-Q · filed 2021-11-08 | -$87.60M derived: sum of 4 quarters · filed 2021-11-08 | ||||
| 2020-06-30 | -$45.07M 10-Q · filed 2021-11-08 | -$72.83M 10-Q · filed 2021-08-05 | -$89.42M derived: sum of 3 quarters · filed 2021-11-08 | -$111.78M derived: sum of 4 quarters · filed 2021-11-08 | ||||
| 2020-03-31 | -$27.75M 10-Q · filed 2021-11-08 | -$44.35M derived: sum of 2 quarters · filed 2021-11-08 | -$66.70M derived: sum of 3 quarters · filed 2021-11-08 | -$94.79M derived: sum of 4 quarters · filed 2021-11-08 | ||||
| 2019-12-31 | -$16.60M 10-K · filed 2021-02-25 | -$38.95M derived: sum of 2 quarters · filed 2021-02-25 | -$67.04M derived: sum of 3 quarters · filed 2021-02-25 | -$84.71M 10-K · filed 2022-02-23 | ||||
| 2019-09-30 | -$22.35M 10-K · filed 2021-02-25 | -$50.44M derived: sum of 2 quarters · filed 2021-02-25 | -$68.11M 10-Q · filed 2020-11-05 | -$80.41M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-06-30 | -$28.09M 10-K · filed 2021-02-25 | -$45.76M 10-Q · filed 2020-08-06 | -$58.05M derived: sum of 3 quarters · filed 2021-02-25 | -$68.87M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2019-03-31 | -$17.67M 10-K · filed 2021-02-25 | -$29.96M derived: sum of 2 quarters · filed 2021-02-25 | -$40.78M derived: sum of 3 quarters · filed 2021-02-25 | -$54.31M derived: sum of 4 quarters · filed 2021-02-25 | ||||
| 2018-12-31 | -$12.29M 10-K · filed 2020-03-05 | -$23.11M derived: sum of 2 quarters · filed 2020-03-05 | -$36.64M derived: sum of 3 quarters · filed 2020-03-05 | -$49.59M 10-K · filed 2021-02-25 | ||||
| 2018-09-30 | -$10.81M 10-K · filed 2020-03-05 | -$24.34M derived: sum of 2 quarters · filed 2020-03-05 | -$37.30M 10-Q · filed 2019-11-05 | -$50.51M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2018-06-30 | -$13.53M 10-K · filed 2020-03-05 | -$26.49M 10-Q · filed 2019-08-06 | -$39.70M derived: sum of 3 quarters · filed 2020-03-05 | -$62.82M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2018-03-31 | -$12.95M 10-K · filed 2020-03-05 | -$26.16M derived: sum of 2 quarters · filed 2020-03-05 | -$49.29M derived: sum of 3 quarters · filed 2020-03-05 | -$58.84M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2017-12-31 | -$13.21M 10-K · filed 2019-03-05 | -$36.33M derived: sum of 2 quarters · filed 2019-03-05 | -$45.88M derived: sum of 3 quarters · filed 2019-03-05 | -$53.08M 10-K · filed 2019-03-05 | ||||
| 2017-09-30 | -$23.12M 10-K · filed 2019-03-05 | -$32.67M derived: sum of 2 quarters · filed 2019-03-05 | -$39.87M 10-Q · filed 2018-11-08 | |||||
| 2017-06-30 | -$9.55M 10-K · filed 2019-03-05 | -$16.75M 10-Q · filed 2018-08-06 | ||||||
| 2017-03-31 | -$7.20M 10-K · filed 2019-03-05 | |||||||
| 2016-12-31 | -$17.97M 10-K · filed 2019-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |